Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | B2M L13fs B2M LOH |
Therapy | Pembrolizumab |
Indication/Tumor Type | melanoma |
Response Type | predicted - resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
B2M L13fs B2M LOH | melanoma | predicted - resistant | Pembrolizumab | Case Reports/Case Series | Actionable | In a clinical case study, a melanoma patient with acquired B2M loss of heterozygosity (LOH) and L13fs did not respond to Keytruda (pembrolizumab) treatment (PMID: 29070816). | 29070816 |
PubMed Id | Reference Title | Details |
---|---|---|
(29070816) | Resistance to checkpoint blockade therapy through inactivation of antigen presentation. | Full reference... |